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Abstract
Background:  Implantation in humans involves cross talk between an active blastocyst and
receptive endometrium. The role of the endometrial receptors in this complex embryo-maternal
interaction is still unclear. We tested gene and protein expression of endometrial receptors
(Progesterone receptor (PR) and c-Met) and the effect of theses receptors in endometrial
receptivity.
Methods: Two endometrial cell lines were used: HEC-1A and RL95-2 considered as being of low
and high receptivity, respectively. Western blot and RT-PCR analysis were utilized to study the
receptor expression profile.
The role of endometrial receptors in endometrial receptivity was studied by attachment and
invasion assays of JAR spheroids (made of a trophoblast cell line) on endometrial cells. Different
manipulations of inhibition and stimulation of the endometrial receptors were used including:
inhibition by specific antibodies against the receptors, or antagonist of the receptors, as well as
transfection with antisense for the endometrial receptors, stimulation by specific ligands for the
receptors and transfection with the gene for endometrial receptors.
Results: Different protein expression patterns of endometrial receptors were observed between
the tested endometrial cell lines. The expression levels of PRA ratio to PRB, and the 50 kDa c-MET
isoform were significantly lower in HEC-1A as compared with RL95-2. Attachment rates and
growth of JAR spheroids into HEC-1A were significantly lower as compared with RL95-2.
Stimulation of PR with progesterone altered attachment rates to HEC-1A. Inhibition of PR with
RU-486 mildly increased attachment rate to HEC-1A whereas it slightly decreased attachment rate
to RL95-2. c-Met inhibition decreased attachment rates only to HEC-1A cells that expressing high
levels of Plexin-B1 (PB1). Immunoprecipitation studies revealed that c-Met and PB1 associate in
complexes in the endometrial cell lines.
Conclusion:  Differential endometrial receptor profiles are expressed during the receptivity
period. The attachment and invasion processes are separately regulated. We suggest a biologically
functional role for PRA in endometrial receptivity and in the attachment process. c-Met
contribution is minor and related with creation of a complex with PB1.
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Background
Implantation in humans involves complex interactions
between the embryo and the maternal endometrium [1-
3]. Successful implantation depends on a pre-implanta-
tion embryo developing into a competent blastocyst that
reaching the uterus precisely at its receptive stage [4].
Endometrial receptivity is suggested to be a property of
the endometrial epithelial cells (EECs). The molecular
mechanisms by which the surface of human EECs
acquires morphological changes, leading to receptive fea-
tures, are still unclear. Cytokines, growth factors, hor-
mones, extracellular matrix proteins and enzymes,
angiogenic factors, cell-cell adhesion molecules and
receptors are all involved in this complex process [5]. Pre-
vious studies demonstrated the appearance of morpho-
logical or biological markers for endometrial receptivity
[6-10]. However functional physiological markers are still
unknown. The cross talk, between the active blastocyst
and the receptive uterus, is solely reliant on mediation
and interrelationship by a variety of receptors in the
endometrium. Despite the possibility of extra corporal
fertilization and extensive new technology, the process of
implantation and the interaction between maternal
endometrium and invading trophoblast are even today
difficult to explore.
Hence, the search for better understanding of this process
continues and is transferred into the in vitro setting [11-
13]. In our previous study [14] we showed that Plexin B1
(PB1), a membrane receptor, has a role in endometrial
receptivity and in the attachment process. The current
study was designed to explore and compare the expression
and role of the membrane receptor c-Met, which is known
to be expressed as a complex with PB1 [15,16] and the
nuclear receptor PR in two human endometrial cell lines,
RL95-2 and HEC-1A, used as a model for high receptivity
and low receptivity endometrium respectively [17-20].
The progesterone receptor (PR) is a member of a large
family of ligand-activated nuclear transcription regula-
tors, which are characterized by organization into specific
functional domains and are conserved between species
and family members. The PR is made up of a central DNA
binding domain and a carboxyl-terminal ligand-binding
domain. Studies on human PR indicate that there are at
list 3 different alternatively spliced forms to the PR. Two
of the PR isoforms, namely PR-A and PR-B, mediate the
effects of progesterone. Detailed function studies indicate
that PR-B, in all cellular contexts in-vitro, functions as a
ligand-dependent trans-activator. This in contrast to PR-A,
which in some contexts acts as a ligand-dependent tran-
scriptional repressor of PR-B [21,22]. There is increasing
evidence to date that PR-A and PR-B are functionally dif-
ferent. The PRB/PRA ratio was found to be of clinical
importance in several tissues, [[23], and [24]]. These dif-
ferences are yet to be fully understood. It is the balance
between these two forms that may make it possible for
progesterone to affect such diverse physiological targets.
Progesterone's action has been shown to be essential for
proper endometrial maturation, endometrial receptivity
and the maintenance of pregnancy [25]. These effects of
progesterone are thought to be mediated primarily
through its cognate receptor [21,22]. The establishment of
normal endometrial receptivity appears to be closely asso-
ciated with the down-regulation of epithelial PR [8]. His-
tologic delay is associated with a failure of PR down-
regulation and the lack of normal markers of endometrial
receptivity.
The proto-oncogene Met encodes a transmembrane tyro-
sin kinase of 190 kDa. c-Met is a heterodimer composed
of two disulfide-linked chains of 50 kDa and 140 kDa
[26]. Met is the receptor for hepatocyte growth factor
(HGF) [26-28]. It is frequently over expressed in neoplas-
tic cells and in host tissue. Due to its prominent role in the
control of motility and invasion, it is involved in metasta-
sis formation. The role of c-Met in endometrial receptivity
still needs to be investigated.
Stromal and trophoblast cells produce HGF [29] while its
receptor is expressed in the endometrial epithelia and
stroma [30]. Recent data indicate that signaling activity of
the Met receptor is affected by an association with other
receptors such as RON and PB1 and it was published that
cells expressing the endogenous proteins, PB1 and c-Met,
associate in a complex [15]. In addition it was shown that
membrane-bound semaphorin Sema4D, PB1's ligand,
can trigger the activation of the oncogenic receptor Met,
which is associated with PB1 on the cell surface [16].
Methods
Cell lines
Two endometrial cell lines were used as in vitro model for
endometrial receptivity. Cell line RL95-2 (ATCC catalog
No.CRL-1671), derived from a moderately differentiated
adeno-squamous carcinoma of the endometrium [17]
was used as a model for receptive endometrium [19,20]
Cell line HEC-1A (ATCC catalog No. HTB-112) derived
from human endometrial carcinoma, served as a model
for the non-receptive state [31]. Third cell line was estab-
lished in our laboratory, HEC-1A cells were transfected
with human PB1 (was provided kindly by Prof. Luca
Tamagnone, the transfected cell line named HEC-1A-2.
(HEC-1A-2 was characterized in our previous study [14].
Human trophoblast cell line, JAR (ATCC catalog No. HTB-
144) was used as a model for blastocysts.
Endometrial cell culture
HEC-1A cells were cultured in Meckoy 5A medium (Kib-
butz Beit-Ha'Emek, Israel) containing 10% Fetal CalfReproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
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Serum (FCS) (Kibbutz Beit-Ha'Emek, Israel) and penicil-
lin/streptomycin (Kibbutz Beit-Ha'Emek, Israel) [32].
RL95-2 cells were cultured in DMEM F: 12 medium (Kib-
butz Beit-Ha'Emek, Israel) containing FCS, penicillin/
streptomycin, 2.5 mM Glutamine (Kibbutz Beit-Ha'Emek,
Israel) [17]. Cell cultures were maintained in a humidified
atmosphere containing 5% CO2 at 37°C. RL95-2 cells (1–
2 × 106) and HEC-1-A cells (1–2 × 106) were seeded in 24-
well culture plates for 10 days, and the growth medium
was renewed every 2–3 days. All studies performed with
serum free medium.
Attachment and growth assays
Attachment of JAR spheroids to endometrial cell monolayer
For the attachment assays JAR spheroids were prepared
and tested as described in details elsewhere [33]: briefly, 1
× 106 JAR cells per 10 ml M-199 medium (Kibbutz Beit-
Ha'Emek, Israel) containing 10% FCS and penicillin/
streptomycin were agitated at 37°C on a Comfort shaker
at 200 rpm (12 × g). In order to distinguish JAR spheroids
from underlying endometrial cell lines (HEC-1A and
RL95-2) or primary culture we have labeled the JAR sphe-
roids with the membrane-permeable fluorescent dye
CMFDA (Invitrogen, Dorset, UK) that after enzymatic
cleavage serves as a long-term cytoplasmic marker. Sphe-
roids were agitated at 37°C for 24 hours. Thereafter sphe-
roids were gently delivered with micro denuding pipette
(150  μm diameter) onto a confluent monolayer of
endometrial cell lines (HEC-1A and RL95-2) grown in 24-
wells culture plates in M-199 growth medium containing
1.5% FCS. After 60 minutes of incubation at 37°C the cul-
ture plate was shaken aggressively at 15 × g (VORTEX
GENIE, Scientific Industries, Chicago, U.S.A) for 60 min-
utes. The medium containing unattached spheroids was
collected, and fresh medium was added to the wells. Sphe-
roids remaining in each well were counted using a phase-
contrast microscope or florescence microscope. Spheroids
attachment is expressed as a percentage of seeded sphe-
roids. In certain experiments HEC-1A and RL95-2 cell
lines were pretreated with Progesterone 0–10 μM (Sigma,
ST Louis, MO, USA) or with RU-486 (PR antagonist)
(Sigma, ST Louis, MO, USA). In other experiments
endometrial cell lines were pretreated with antisense
against c-Met (IDT Inc, Hy-Labs, Rehovot, Israel).
Growth of JAR spheroids in endometrial cell monolayer
Spheroids outgrowth was measured under the microscope
for the next 10 days. Each spheroid diameter size was
measured using a special scale in the ocular.
Preparation of whole cell extract and western blot analysis
HEC-1A and RL95-2 cells were lysed on ice in lysis buffer
(20 mM Tris-HCl, pH 7.4, 5 mM EDTA, 150 mM NaCl,
10% glycerol, 1% Triton X-100) in the presence of a mix-
ture of protease inhibitors (Roche, Kulmbach, Germany),
suspensions were incubated for 7 minutes in 4°C. Cell
lysates were precleared by centrifugation at 12000 rpm for
20 minutes, the supernatant fraction contained proteins.
Protein assay
The total protein content of endometrial cells was deter-
mined using a protein assay kit with BSA as the standard
(Bio-Rad laboratories, Inc, Washington DC). One to five
microliters of sample were used in the assay. The assay is
based on the Bradford dye-binding procedure.
Western blot
In order to detect c-Met and PR, whole cell and nuclear
extracts were diluted with 4 × sample buffer (5% SDS,
20% Glycerol in 0.4 M Tris, pH 6.8 containing 0.02%
bromophenol blue) and subjected to 8% polyacrylamide
gel electrophoresis. After electrophoresis, the proteins (50
μg/lane) were blotted from the SDS-PAGE onto 0.45 μm
nitrocellulose membranes (Schleicher & Schuell, Dassel,
Germany). Nonspecific binding sites were blocked by
incubating the nitrocellulose membranes for 1 hour with
5% BSA (Sigma, ST Louis, MO, USA) in Tris-buffered
saline. The membranes were then washed four times with
Tris-buffered saline, containing 0.75% Tween-20, and
incubated for 1 hour with antibodies against PR (Santa
Cruz, Biotech, California, USA sc-539) or c-Met (Santa
Cruz Biotech, California, USA sc-161) in 0.5% BSA in Tris-
buffered saline, containing 0.01% Tween-20. The mem-
branes were subsequently washed with Tris-buffered
saline, containing 0.75% Tween-20 and incubated for 1
hour with HRP-conjugated Horseradish peroxidase-con-
jugated goat anti- rabbit secondary antibody (Jackson
Immuno-research, Enco, Israel) in 0.5% BSA in Tris-buff-
ered saline, containing 0.01% Tween-20. Proteins were
detected by enhanced chemiluminescence (ECL Kit, Kib-
butz Beit-Ha'Emek, Israel,) and quantified using the Bio-
Imaging gel documentation system (Dinco & Renium,
Jerusalem, Israel) endowed with TINA software (Raytest,
Taubenhardt, Germany). PR and c-Met were expressed as
percent of control. For normalization we have used the
levels of the housekeeping protein GAPDH.
Semiquantitative RT-PCR
To analyze the expression of PR and c-Met, total RNA was
prepared from cell cultures with EZ-RNA Kit (Kibbutz
Beit-Ha'Emek, Israel). RNA concentrations were deter-
mined spectrophotometrically. To obtain the cDNA from
cell lines, total RNA (5 μg) was denatured at 70°C for 10
min and then reverse transcribed in the presence of 25 ng/
μl random primer (Promega, Mannheim, Germany), 2.5
mM MgCl2, 0.5 mM deoxy-NTPs, 10 mM dithiothreitol,
and 10 U ribonuclease H- reverse transcriptase (Super-
script II RT, Life Technologies, Inc.) for 60 min at 42°C,
and 5 min at 95°C. Subsequently, 10 μl of the resulting
cDNA was used as a template for polymerase chain reac-Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
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tion (PCR). The PCR was set up using 3 mM MgCl2, 50
pmol of each primer and 2.5 U Taq DNA polymerase
(Sigma, St. Louis, MO, USA).
Primer design: the sequences of the primers were taken
from the Genbank
PRB (Genbank access no. M15716)
PRB FWD 5'- ACACCTTGCCTGAAGTTTCG-3'
PRB REV 5'- CTGTCCTTTTCTGGGGGACT-3' (196 bp
product).
c-MET – (Genbank access no. M35073)
c-MET FWD 5'- CTACAAAGAAGTTGATGAACCG-3'
c-MET REV 5'- GCTGACATACAGTCGGAGG-3' (139 bp
product).
For normalization we have used the levels of the house-
keeping gene GAPDH.
GAPDH FWD 5'-TGATGACATCAAGAAGGTGGTGAAG-
3'; GAPDH REV 5'-TCCTTGGAGGCCATGTGGGCCAT-3'
(230 bp product).
PCR conditions were 94°C for 2 min followed by 35
cycles of 94°C for 30 sec, 58°C for 45 sec, and 72°C for
60 sec with a 72°C extension for 10 min. After PCR, the
products were resolved on a 2.5% agarose ethidium bro-
mide gel. Images were captured with Polaroid (Hertford-
shire, UK) film under UV light. Products were quantified
using PhosphorImager and ImageQuant software (Molec-
ular Dynamics, Inc., Sunnyvale, CA).
Immunoprecipitation
Endometrial cell lines (HEC-1A, RL95-2, HEC-1A-2) were
washed twice in ice cold PBS and lysed on ice in lysis
buffer (20 mM Tris-HCl, pH 7.4, 5 mM EDTA, 150 mM
NaCl, 10% glycerol, 1% Triton X-100) in the presence of
a mixture of protease inhibitors (Roche, Kulmbach, Ger-
many). 500 μg of whole cell extract in 1 ml lysis buffer
were subject for immunoprecipitation and PB1 receptors
were immunoprecipitated by incubation for 2 h on rocker
at 4°C with 1 μg anti-PB1 antibody (Santa Cruz Biotech,
California, USA, sc-28372). Immunocomplexes were
recovered with the aid of 20 μl protein A/G agarose beads
(Santa Cruz Biotech, California, USA, sc-2003). Each sam-
ple was placed on a rocker at 4°C for 1 h and thereafter
incubated for 16 h at 4°C. The beads were washed twice
with 1 ml lysis buffer and twice with Tris-EDTA (TE) and
subsequently the bound proteins were eluted in 50 μl of
1% SDS in TE. Sample buffer was added to the superna-
tant of each sample. Lysates and immunoprecipitates were
analyzed by Western blotting after SDS-polyacrylamide
gel electrophoresis and transfer to a 0.45 μm nitrocellu-
lose membranes (Schleicher & Schuell, Dassel, Germany)
with anti c-Met antibodies (Santa Cruz Biotech, Califor-
nia, USA, sc-161). Proteins were detected by enhanced
chemiluminescence (ECL Kit, Kibbutz Beit-Ha'Emek,
Israel). As a negative control, PB1 immunoprecipitation
was performed, followed by Western blotting with
GAPDH antibody.
Immunofluorescence staining
For immunofluorescence analysis, endometrial cells were
cultured on glass coverslips in 35 μl medium drops under
mineral oil. Cells were washed 3 times with PBS and fixed
with 3.7% paraformaldehyde (Electron Microscope Sci-
ences, Belgar) in PBS for 10 minutes at 4°C, then washed
twice with PBS and permeabilized for 5 minutes at 4°C
with 0.1% Triton (Sigma, St. Louis, MO, USA) in PBS.
After a PBS wash, slides were incubated for 1 hour with
blocking buffer (PBS supplemented with 3% BSA), then
washed 3 times with PBS and incubated for 30 minutes at
room temperature with primary antibodies (Anti c-Met),
1 μg per slide in 700 μl PBS supplemented with 1.5% BSA.
After five washings with PBS, slides were incubated for 30
minutes in the dark with secondary fluorescein-labeled
antibody (for F-actin:phalloidin, AlexaFlour-488, A-
12379; for c-Met: goat anti-rabbit IgG conjugated with
AlexaFlour-546, all from Molecular Probes, Invitrogen,
Dorset, UK), 0.5 μg per slide in 700 μl PBS supplemented
with 1.5% BSA. Following three washings with PBS,
stained cells were photographed using a confocal micro-
scope (the confocal system is composed of a Bio-Rad radi-
ance 2000 confocal set-up hooked to an upright
fluorescent microscope Nikon E600 with a 60X lens). The
photos were analyzed by Image Pro software (Media
Cybernetics, Bethesda, USA), which quantifies density per
area.
Statistical analysis
Results are expressed as mean ± SEM, with n denoting the
number of spheroids. Student's t-test, chi test and "one
way analysis of variance" (ANOVA) were used when
appropriate. P < 0.05 was considered significant.
Results
PR expression in RL95-2 and HEC-1A cells
PRB gene expression was studied by RT-PCR. For normal-
ization we have used the levels of the housekeeping gene
GAPDH. In order to exclude the possibility of fluctuation
in gene expression during 24 hours (h) period, we have
studied the basal PRB gene expression on 2, 12 and 24 h
of incubation with serum-free medium, 2 h after medium
replacement considered as starting period (time 0).Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
Page 5 of 14
(page number not for citation purposes)
Figure. 1A shows representative 196 bp product of human
PRB cDNA. The ratio between the expression level of PRB
and GAPDH of each independent experiment from the
same cell line under the same treatment was analyzed. The
accumulated ratio found to be significantly lower in HEC-
1A as compared with RL95-2 cells (ratio 0.084 ± 0.08 ver-
sus 0.44 ± 0.13 ratio, respectively, * P < 0.05, Figure. 1B).
In order to further validate our results, we examined
nuclear and cytosolic lysates from monolayer of each cell
line cultured in the same conditions that were used for
spheroids attachment assays. Western blot analysis was
conducted using sc-539 antibody against PR. We deter-
mined the presence of PR isoforms: the 116 kDa PRB iso-
form, the 82 kDa PRA isoform and the N-terminally
truncated 60 kDa PRC expressed in the cytosol and
nuclear fractions. PRB/PRA ratio was calculated for each
lane separately. The PRB/PRA ratio in RL95-2 was consid-
ered 100 percent. The results are expressed as percent of
RL95-2. PRB/PRA ratio in the nucleus of HEC-1A cells was
found to be significantly higher as compared with RL95-2
(208% ± 8.8 versus 100% respectively, * P < 0.001, Figure.
1D). In the cytosolic fraction there was no significant dif-
ference in the PRB/PRA ratio in HEC-1A cells as compared
with RL95-2 (71% ± 12 versus 100% respectively, Figure.
1D).
The effect of progesterone on spheroid attachment in 
endometrial cell lines
In order to study the effect of PR stimulation on JAR sphe-
roids attachment to endometrial cell lines, we added pro-
gesterone to HEC-1A, the low receptivity cells. A confluent
monolayer of HEC-1A cell line was incubated with or
without progesterone (0–10 μM) at 37°C and attachment
assays were conducted. A total of 1,274 JAR spheroids
were divided and examined in HEC-1A cultures treated
with different progesterone concentration (n = 239 on
treated HEC-1A with 0.018 μM progesterone, n = 258 on
treated HEC-1A with 0.18 μM progesterone, n = 233 on
treated HEC-1A with 1.78 μM progesterone, n = 185 on
treated HEC-1A with 4.5 μM progesterone, n = 94 on
treated HEC-1A with 6.7 μM progesterone, n = 67 on
PR expression in endometrial cell lines Figure 1
PR expression in endometrial cell lines. (A) Transcript expression level of PRB in HEC-1A versus RL95-2 cells. Repre-
sentative agarose gel of RT-PCR for PRB and GAPDH in HEC-1A and RL95-2 cells. Product size: PRB 196 bp, GAPDH 230 bp. 
(B) Bar graph describing the mean ± SEM of the ratio between the expression level of PRB/GAPDH, black bars represent HEC-
1A, white bars represent RL95-2, * P < 0.05, ND not detected. (C) Representative Western blots from nuclear and cytosol 
extracts of PRB (116 kD), PRA (82 kD) and PRC (60 kD) expression patterns. (D) Bar graph describing mean ± SEM of the 
percentage of PRB/PRA ratio in HEC-1A from RL95-2, black bars represent HEC-1A, white bars represent RL95-2, * P < 0.05.
B
*
NC  2   12  24  2   12   24   bpl   NC  2   12    24   2    12   24 
A
2 12    24
Time (hours)
GAPDH 
230bp PRB 
196bp
HEC-1A  RL95-2 HEC-1A    RL95-2
R
a
t
i
o
 
P
R
B
/
G
A
P
D
H
HEC-1A
RL95-2
PRB 116kDa
PRA 82kDa
PRC 60kDa
HEC-1A                   RL95-2
Cytosol   Nuclear   Cytosol   Nuclear 
0
50
100
150
200
250
300
P
e
r
c
e
n
t
a
g
e
 
o
f
 
P
R
B
/
P
R
A
 
r
a
t
i
o
Nuclear                                   Cytosol  
*
C
D
ND
0
0.2
0.4
0.6
0.8
1Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
Page 6 of 14
(page number not for citation purposes)
treated HEC-1A with 10 μM progesterone, and n = 198 on
un-treated HEC-1A cells). As shown in Figure. 2A, we
found a dual effect of progesterone, at low concentration
of 0.018 μM progesterone significantly inhibited spheroid
attachment to treated HEC-1A cells as compared to non-
treated HEC-1A cells (13.7% ± 0.47 versus 26.5% ± 3.78,
respectively) while a higher progesterone concentration of
6.7 μM and 10 μM increased the attachment rate as com-
pared with non-treated HEC-1A cells (39.8% ± 3.87 and
34.3% ± 0.43 versus 26.5% ± 3.78, respectively, * P <
0.05). RL95-2 is high receptivity cells therefore we tested
the low concentration of progesterone, the inhibitory con-
centrations, (0–0.18 μM). As shown in Figure. 2B JAR
spheroid attachment rate to RL95-2 was not affected by
progesterone.
The effect of PR antagonist RU-486 on spheroid 
attachment in endometrial cell lines
It is well known that progesterone effect is mediated by its
cognate receptor – PR. In order to further investigate the
role of the PR during the implantation process we tested
the effect of PR inhibition on spheroids attachment. We
conducted attachment assays to endometrial cell lines
treated with RU-486 (10-6 M) PR antagonist. A confluent
monolayer of HEC-1A and RL95-2 cell lines was incu-
bated with or without RU-486 for 24 hours before sphe-
roids deliver. In three experiments a total of 270 JAR
spheroids were divided and examined in HEC-1A cell cul-
tures (n = 134 on treated cells and n = 136 on non-treated
cells) The JAR spheroid attachment rate to HEC-1A treated
with RU-486 increased as compared with non-treated
cells (89.5% ± 1.7 versus 75.5% ± 2.8 respectively, * P <
JAR spheroid attachment to HEC-1A and RL95-2 cells with or without Progesterone Figure 2
JAR spheroid attachment to HEC-1A and RL95-2 cells with or without Progesterone. (A) Bar graph describes 
mean ± SEM of % attachment to HEC-1A cells treated with progesterone (0–10 μM), * P < 0.05. (B) Bar graph describes mean 
± SEM of % attachment to RL95-2 cells treated with progesterone (0–0.18 μM). JAR spheroid attachment to HEC-1A and 
RL95-2 cells with or without PR antagonist RU-486. (C) Bar graph describes mean ± SEM of % attachment to HEC-1A cells 
treated with RU-486 (10-6 M). (D) Bar graph describes mean ± SEM of % attachment to RL95-2 cells treated with RU-486 (10-
6 M). * P < 0.05.Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
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0.01, Figure. 2C). In four experiments a total of 302 JAR
spheroids were divided and examined in RL95-2 cell cul-
tures (n = 148 on treated cells and n = 154 on un-treated
cells). In contrast, in RL95-2 cells, RU-486 decreased the
attachment rates of JAR spheroids to treated cells as com-
pared with non-treated cells (96.7% ± 2.1 versus 86.2% ±
3.7 respectively, * P < 0.05, Figure. 2D).
c-Met expression in RL95-2 and HEC-1A cells
c-Met gene expression was studied by RT-PCR. For nor-
malization we have used the levels of the housekeeping
gene GAPDH. In order to exclude the possibility of fluctu-
ation in gene expression during 24 h period, we have stud-
ied the basal c-Met gene expression on 2, 12 and 24 h. 2 h
after medium replacement considered as starting period
(time 0).
Figure. 3A shows representative 139 bp product of human
c-Met cDNA. The ratio between the expression level of c-
Met and GAPDH of each independent experiment from
the same cell line under the same treatment was analyzed.
The ratio in RL95-2 was considered as 100%, the results
expressed as % of RL95-2 (Figure. 3B). There was no dif-
ference in transcript expression level of c-Met between the
two cell lines.
In order to study whether c-Met protein is expressed
equally in both cell lines, we examined cell lysates from
monolayer of each cell line cultured in the same condi-
tions that were used for spheroids attachment assays.
Western blot analysis was conducted using sc-161 anti-
body against c-Met. We determined the presence of two
bands in endometrial cell lines (140 and 50 kDa, Figure.
3C). The ratio between the expression level of the short
form of c-Met (50 kDa) to the long form (140 kDa) was
analyzed for each independent experiment, under the
same treatment. In both HEC-1A and HEC-1A-2 the
expression level of the 50 kDa form was lower as com-
pared to the 140 kDa form of c-Met. These results are con-
trary to c-Met's expression pattern in RL95-2 (Figure. 3C).
c-MET expression in endometrial cell lines Figure 3
c-MET expression in endometrial cell lines. (A) Representative agarose gel of RT-PCR for c-MET and GAPDH in HEC-
1A and RL95-2 cells. Product size: c-MET 139 bp, GAPDH 230 bp. (B) Bar graph describing mean ± SEM of the percentage of 
c-MET/GAPDH ratio in HEC-1A from RL95-2, black bars represent HEC-1A, white bars represent RL95-2. (C) Representative 
Western blots from whole cell extract of HEC-1A, RL95-2 and HEC-1A-2 cells. Full length of c-MET – 140 kD, short form – 50 
kD. (B) Bar graph describing mean ± SEM of the 50 kDa/140 kDa ratio in HEC-1A, RL95-2 and HEC-1A-2, black bar represents 
HEC-1A; white bar represents RL95-2; gray bar represents HEC-1A-2, * P < 0.05.Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
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The c-Met forms 50 kDa/140 kDa ratio for HEC-1A and
HEC-1A-2 was 0.47 ± 0.07 and 0.43 ± 0.09 respectively,
versus 2.56 ± 0.43 for RL95-2, * P < 0.05 (Figure. 3D).
The expression pattern of HGF, the specific ligand of c-
Met, in JAR cells and endometrial cell lines was studied by
western blot analysis. As shown in Figure. 4E all the tested
cells expressed high level of HGF. This result directed us to
perform inhibition of c-Met in order to study the role of
the receptor in endometrial receptivity.
The effect of c-Met inhibition on spheroid attachment to 
endometrial cell lines
c-Met does not have any known specific inhibitor, so we
used c-Met antisense to get the required inhibition. To
determine if manipulation on c-Met expression using the
antisense (AS) method might alter JAR spheroid attach-
JAR spheroid attachment to endometrial cell lines, with or without c-MET antisense Figure 4
JAR spheroid attachment to endometrial cell lines, with or without c-MET antisense. (A) Representative immuno-
flouroscent labeling for c-MET expression in HEC-1A, RL95-2 and HEC-1A-2 cells with or without c-MET antisense. (B) Bar 
graph describes mean ± SEM of % attachment (black bars) to HEC-1A, RL95-2 and HEC-1A-2 cells treated with c-MET anti-
sense (grey bars), * P < 0.05.Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
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ment to endometrial cell lines we conducted attachment
assays to HEC-1A, RL95-2 and HEC-1A-2 cells, transfected
with c-Met antisense. Figure. 4A shows immunofluro-
cense staining for c-Met expression in endometrial cell
lines. The c-Met expression level in the transfected cells is
lower compared with the un-transfected cells.
JAR spheroids were added to a confluent monolayer of
transfected or un-transfected cells and the attachment
rates were measured. In five experiments a total of 482 JAR
spheroids were divided and examined in endometrial cell
cultures (n = 83 on transfected HEC-1A cells and n = 78
on un-transfected HEC-1A cells, n = 82 on transfected
RL95-2 cells and n = 82 on un-transfected RL95-2 cells, n
= 79 on transfected HEC-1A-2 cells and n = 78 on un-
transfected HEC-1A-2 cells). Inhibition of c-Met expres-
sion by using the antisense method significantly
decreased the attachment rate of JAR spheroids to treated
HEC-1A-2 cells as compared to non-treated HEC-1A-2
cells (71.3% ± 2.78 versus 91.7% ± 0.28 respectively, p <
0.01, Figure. 4B). c-Met antisense treatment did not alter
the JAR spheroid attachment rate to treated HEC-1A and
to treated RL95-2 cell lines (for HEC-1A: 78.2% ± 7.4 ver-
sus 72.3% ± 4.5, for RL95-2: 92.2% ± 2.6 versus 96.5% ±
2.6, treated and un-treated respectively, Figure. 4B). As it
was expected, according to our previous study (Harduf et
al, 2007), the attachment rate of JAR spheroids to RL95-2
is significantly higher as compared to HEC-1A (Figure.
4B).
Association of PB1 and c-Met
With regard to JAR spheroids attachment, HEC-1A-2,
which expressed high level of PB1, was the only cell line
that affected following c-Met inhibition. In order to fur-
ther investigate the possible function of c-Met in the
implantation process, we examined if c-Met associates
with the intracellular portion of PB1. In six independent
experiments, lysates of HEC-1A, RL95-2 and HEC-1A-2
cells were immunoprecipitated for the PB1 receptor (IP:
PB1) and immunoblotted for the presence of c-Met (WB:
c-Met), using antibodies against c-Met.
As a negative control, PB1 immunoprecipitation was per-
formed followed by Western blotting with GAPDH anti-
body (WB: GAPDH). As shown in Figure. 5, the higher
panel represents the presence of the 140 kDa isoform of c-
Met, while the mid panel represents the presence of the 50
kDa isoform of c-Met. The input extract contains all the
proteins of the tested cells while the IP extract contains
just the proteins associated with PB1. Complexes of PB1
with the 140 kDa isoform of c-Met were observed in HEC-
1A, RL95-2 and HEC-1A-2 cells. Complexes of PB1 with
the 50 kDa isoform of c-Met were observed in RL95-2 and
Immunoprecipitation of c-MET with PB1 Figure 5
Immunoprecipitation of c-MET with PB1. Representative Western blots from whole cell extract of HEC-1A, RL95-2 and 
HEC-1A-2 cells. Endometrial cells were lysed, and protein in equal amounts (500 μg) was subjected to immunoprecipitation 
with PB1 antibodies (IP: PB1), followed by Western blotting with c-MET antibody (WB: c-MET). c-MET was observed mainly in 
immunoprecipitates from RL95-2 and HEC-1A-2. Lower lane represents negative control of PB1 immunoprecipitation, and 
Western blotting with GAPDH antibody (WB: GAPDH).Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
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HEC-1A-2 cells. Complexes of PB1 with GAPDH were not
observed in the tested cells (Figure. 5).
Discussion
Progesterone, estrogen and their cognate receptors are crit-
ical and essential regulators of uterine receptivity [34,35].
PR was identified in the nuclei of epithelial cells, stromal
cells, and myometrial smooth muscle cells of the uterus.
The PR content of endometrial epithelium and stroma
varies with the menstrual cycle. The epithelium demon-
strated very strong PR expression during the proliferative
phase and in the early secretory phase while at the post-
ovulation phase it decreased sharply [8]. In general, there
was homogeneous expression of the two isoforms in
nuclei within the same tissue compartment during most
stages of the menstrual cycle, although there were excep-
tions [36]. However according to another study expres-
sion of only one isoform, either PRA or PRB, is common
[37]. The mRNA expression of PRB was high in RL95-2
and low in HEC-1A. However, at the protein level the PRB
expression was high in HEC-1A and low in RL95-2. Dis-
crepancy between the abundance of RNA molecules and
the cognate protein has been recently reviewed [38]. Pro-
tein and RNA represent different steps of a multi-stepped
cellular genetic information process, in which under dif-
ferential-regulatory steps they are dynamically produced
and degraded. The current study results suggest posttran-
scriptional modulation of PRB expression in these cells.
During the proliferative phase of the menstrual cycle, high
levels of both PRA and PRB were noted in the epithelium.
The intensity of PR staining increased during the prolifer-
ative phase, reaching maximal levels in the mid- to late
proliferative phase, and a similar increase in levels of PRA
and PRB was evident. By the mid-secretory phase,
although overall PR protein concentrations were still fur-
ther reduced, predominant expression of the PRB isoform
was demonstrated [36].
In our study, we found significantly lower PRB protein
expression level in RL95-2 as compared with HEC-1A
cells. Moreover, the PRB/PRA ratio in the nucleus of RL95-
2 cells is significantly lower as compared with HEC-1A.
RL95-2 represents receptive epithelial endometrium cells
during window of implantation or early secretory phase,
while HEC-1A represents epithelial endometrium cells
out of the window of implantation. Our results are seem-
ingly contradictory with previous studies, which had dem-
onstrated earlier down regulation of nuclear PRA during
early secretory phase in epithelium endometrial cells,
while PRB was the predominant isofrm at this stage
[36,8]. This difference may be due to the difference in
measurement techniques between the two studies.
The distribution of PR subtypes may have important clin-
ical consequences. Both the A and B isoforms of PR are
capable of binding progesterone and dimerizing and
interacting with progesterone-responsive elements, as
well as the transcriptional machinery to regulate gene
expression. A growing body of evidence has accumulated
in recent years demonstrating that the PRA and PRB pro-
teins are functionally different. PRB has a higher activity
in response to progesterone stimulation [39]. In addition,
they may regulate different physiological target genes in
response to progesterone, and each protein may display
different trans-activation capabilities in different target tis-
sues [40]. It is the balance between these two forms that
may make it possible for progesterone to affect such
diverse physiological targets [41,39].
To facilitate uterine remodeling for embryo attachment,
progesterone is known to attenuate estrogen-induced
gene expression in uterine epithelial cells. Intriguingly,
this suppression is mediated by stromal PR, suggesting
that the coordinated action of estrogen and progesterone
depends on cross talk between the epithelial and stromal
compartments of the uterus. The mechanism by which
progesterone suppresses estrogen's action remains poorly
defined [35]. PRA was implicated as the more important
mediator of stromal- epithelial interaction [41]. More
recently, selective ablation of the PRA and PRB proteins in
mice had facilitated examination of the contribution of
the individual PR isoforms to the reproductive activities of
progesterone. Ablation of PRA results in severe abnormal-
ities in ovarian and uterine function leading to female
infertility, whereas ablation of PRB does not affect either
ovarian or uterine function. The anti-proliferative and
anti-inflammatory roles of PR, both of which are anti-
estrogenic, may be imparted primarily by the A protein
[39]. Thus, PRA is both necessary and sufficient to elicit
the progesterone-dependent reproductive responses nec-
essary for female fertility [42]. This report is consistent
with our finding that PRA is the dominant isoform in
RL95-2.
In order to study the involvement of PR in spheroid
attachment to endometrial cell lines, we stimulated PR
with progesterone. A dual progesterone effect was found
in HEC-1A cells (low concentration of progesterone sig-
nificantly inhibited spheroids attachment, while higher
concentrations of progesterone increased attachment
rates to HEC-1A cells). It is well known that progesterone
function in regard to trophoblast-endometrium interac-
tion is dose-dependent [43] and that the progesterone
response is biphasic [44].
Attachment rates of JAR spheroids to RL95-2 were not
altered in response to low concentrations of progesterone.
It might be explainable by the different dominant PR iso-
form in those cells: PRA in RL95-2 and PRB in HEC-1A
cells.Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
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Progesterone is known to control cell adhesion proteins
including ECM proteins and their cellular receptors,
integrins. It was shown that progesterone upregulates the
expression of these molecules [45,46]. It might be sug-
gested that progesterone's action in increasing the attach-
ment rate occurs via integrin stimulation.
In our study, PR antagonist RU-486 appeared to decrease
the JAR spheroid attachment rate to RL95-2 cells by 10%,
while it increased the attachment rate of JAR spheroids to
HEC-1A cells by 18.5%. In accordance with our study it
was shown that RU-486 inhibits the expression of
endometrial receptivity markers (LIF, Integrin αVβ3,
MUC1) and also inhibits attachment of human embryos
to an in-vitro endometrial construct [47,48]. It was shown
that the potent progesterone antagonist RU-486 has the
potential to acquire substantial agonist activity in
response to stimulation of cAMP signaling pathways.
Moreover, agonist activity appears to be the result of
authentic RU-486 activity through the PR [49]. There is
significant implication for the PR subtype in regarding to
RU-486 effect. It was documented that the ratio of PR iso-
forms B/A strongly influences the direction of a tissue's
response to progesterone antagonists [50]. It might be
suggested that RU-486 acts differently on each of the
endometrial cell lines. In HEC-1A the dominant isoform
is PRB. Inhibition of it by RU-486 changed the ratio PRB/
PRA and elevated the relative amount of PRA, which
seemed to be involved in the attachment process. Never-
theless it requires further investigation.
The expression pattern of c-Met and its biological role
have been studied in various tumors, but, as yet, these
findings have not been incorporated into the implanta-
tion studies. We undertook this study to characterize the
expression pattern of c-Met and to determine whether c-
Met is a potential target for trophoblast epithelial interac-
tion. There was no difference in transcript expression level
of c-MET between the two cell lines. However at the pro-
tein level we found a different expression profile in the
two cell lines. The ratio of 50 kDa/140 kDa of c-Met iso-
forms was found to be significantly lower in the HEC-1A
cell line as compared to RL95-2. The c-Met expression pat-
tern in HEC-1A-2 was similar to the pattern observed in
HEC-1A. Nevertheless, the ratio 50 kDa/140 kDa of c-Met
isoforms were lower in the first.
The Met proto-oncogene encodes a transmembrane tyro-
sine kinase of 190 kDa (p190MET), which has recently
been identified as the receptor for hepatocyte growth fac-
tor/scatter factor (HGF). p190Met is a heterodimer com-
posed of two disulfide-linked chains of 50 kDa (p50
alpha) and 145 kDa (p145 beta). It is believed that the
truncated 50 kDa form is a cytosolic form called cyto-Met
[51]. This form is suggested to be degraded by rapidly
polyubiquitinated [52]. It was also hypothesized that the
production of the C-terminal truncated Met forms may
have a physiological role in modulating the Met receptor
function [53]. They interfere with the Met receptor signal
transduction pathway by competing with the intact recep-
tor for binding to the ligand. Such a negative regulatory
role has already been shown. Moreover, the transmem-
brane truncated receptors, devoid of tyrosine kinase activ-
ity, may form inactive heterodimers with the intact
receptors [54,26].
It was suggested that in mouse the presence of the shorter
variant transcript and its corresponding protein isoform
in a variety of normal tissues has a unique physiological
role [55]. Thus it might explain our observation of a dif-
ferent expression profile of the two forms of c-MET recep-
tor between the cell lines, which differ in their receptivity
potential.
According to our results, c-Met AS was sufficient to inhibit
spheroid attachment to HEC-1A-2 cells but not to HEC-
1A or RL95-2. The only difference between RL95-2 and
HEC-1A-2 is the higher expression level of the truncated c-
Met form and between the HEC-1A and HEC-2A is the
higher PB1 expression level in the latter. It was published
that cells expressing the endogenous proteins, PB1 and c-
Met, associate in a complex [56,57,15]. In addition, bind-
ing of Sema 4D to PB1 stimulates the tyrosine kinase
activity of c-Met, resulting in tyrosine phosphorylation of
both receptors [15]. This suggests that integration of cell-
restricted expression of receptor partners that modulate
kinase outputs with the intrinsic signaling features of
receptors is required for specification of biological
responses. In this study we suggest that c-Met interacts
with PB1 in all endometrial cell lines. However, a high
interaction was observed in HEC-1A-2 and RL95-2, which
is not surprising since PB1 expression level is significantly
higher in these cell lines. However this scenario is proba-
bly more complex because plexins can interact with a vari-
ety of growth factors and receptors [58].
Conclusion
Attachment and invasion processes seem to be separately
regulated. The findings of differential c-Met and PR profile
expressed during the receptivity period may have impor-
tant implications. PRA is most probably involved in
endometrial receptivity and in the attachment process. c-
Met is creating a complex with PB1 contributing to the
regulation of endometrial receptivity and the attachment
process.
We hypothesized that before cells attachment, an interac-
tion between the endometrial blastocyst receptors occurs.
Consequently cell-cell attachment followed by cell adhe-Reproductive Biology and Endocrinology 2009, 7:14 http://www.rbej.com/content/7/1/14
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sion open the door for the beginning of successful
implantation (Figure. 6)
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